The real-life effectiveness of palivizumab for reducing hospital admissions for respiratory syncytial virus in infants residing in Nunavut

BACKGROUND⁄ Nunavut has the highest hospitalization rates for respiratory syncytial virus (RSV) worldwide, with rates of 166 per 1000 live births per year

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Canadian respiratory journal 2014, Vol.21 (3), p.185-189
Hauptverfasser:	Banerji, Anna, Panzov, Vladimir, Young, Michael, Lee, Bonita E, Mamdani, Muhammad, Giles, B Louise, Dennis, Marguerite, Morel, Johanne, Bisson, Danny, Paes, Bosco A, Hui, Charles, Mahony, Jim
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal, Humanized - therapeutic use Antiviral Agents - therapeutic use Hospitalization - statistics & numerical data Humans Infant Infant, Newborn Infant, Premature Infant, Premature, Diseases - diagnosis Infant, Premature, Diseases - ethnology Infant, Premature, Diseases - prevention & control Inuits Nunavut Original Palivizumab Population Surveillance Prospective Studies Respiratory Syncytial Virus Infections - diagnosis Respiratory Syncytial Virus Infections - ethnology Respiratory Syncytial Virus Infections - prevention & control Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	BACKGROUND⁄ Nunavut has the highest hospitalization rates for respiratory syncytial virus (RSV) worldwide, with rates of 166 per 1000 live births per year
ISSN:	1198-2241 1916-7245
DOI:	10.1155/2014/941367